Topical and Transdermal Drug Products

Total Page:16

File Type:pdf, Size:1020Kb

Topical and Transdermal Drug Products STIMULI TO THE REVISION PROCESS Stimuli articles do not necessarily reflect the policies Pharmacopeial Forum 750 of the USPC or the USP Council of Experts Vol. 35(3) [May–June 2009] Topical and Transdermal Drug Products The Topical/Transdermal Ad Hoc Advisory Panel for the USP Performance Tests of Topical and Transdermal Dosage Forms: Clarence T. Ueda (Chair), Vinod P. Shah (USP Scientific Liaison), Kris Derdzinski, Gary Ewing, Gordon Flynn, Howard Maibach, Margareth Marques (USP Scientific Liaison),a Howard Rytting,b Steve Shaw, Kailas Thakker, and Avi Yacobi. ABSTRACT This Stimuli article provides general information about the test methods that should be employed to ensure the quality and performance of topical and transdermal drug products. The term topical drug products refers to all formulations applied to the skin except transdermal delivery systems (TDS) or transdermal patches that will be addressed separately. INTRODUCTION Therefore, the in vitro release test for those products also may differ significantly and may require different Drug products topically administered via the skin fall types of apparatus. At present, a product performance into two general categories, those applied for local action test exists only for semisolid formulations, specifically and those for systemic effects. Local actions include creams, ointments, and gels. That test employs the ver- those at or on the surface of the skin, those that exert tical diffusion cell (VDC) system. The VDC system is sim- their actions on the stratum corneum, and those that ple to operate and yields reliable and reproducible results modulate the function of the epidermis and/or the der- when employed by properly trained laboratory person- mis. Common products in the former category include nel. creams, gels, ointments, pastes, suspensions, lotions, TDS or transdermal patches are physical devices ap- foams, sprays, aerosols, and solutions. Creams, oint- plied to the skin and vary in their composition and meth- ments, and gels generally are referred to as semisolid od of fabrication. Therefore, they release their active Stimuli to the Revision Process dosage forms. The most common drug products applied ingredients by different mechanisms. to the skin for systemic effects are referred to as self- adhering transdermal drug delivery systems (TDS) or GLOSSARY OF TERMS transdermal patches. Two categories of tests, product quality tests and prod- Definitions of topical drug products, some aspects re- uct performance tests, are performed with drug products lated to the manufacture of these products, and a glos- to provide assurances of batch-to-batch quality, reprodu- sary of dosage form names commonly used can be found cibility, reliability, and performance. Product quality tests in General Information Chapter Pharmaceutical Dosage are performed to assess attributes such as assay, identifi- Forms h1151i. cation, content uniformity, pH, microbial limits, and minimum fill and are part of the compendial mono- Collodion graph. Product performance tests are conducted to as- sess drug release from the finished dosage form. Collodion (pyroxylin solution; see USP monograph), is This Stimuli article provides general information about a solution of nitrocellulose in ether and acetone, some- the test methods that should be employed to ensure the times with the addition of alcohol. As the volatile solvents quality and performance of topical and transdermal drug evaporate, a dry celluloid-like film is left on the skin. Be- products. The term topical drug products refers to all for- cause the medicinal use of a collodion depends on the mulations applied to the skin except transdermal delivery formation of a protective film, the film should be durable, systems (TDS) or transdermal patches that will be ad- tenacious in adherence, flexible, and occlusive. dressed separately. Topical dosage forms include solutions (for which re- Creams lease testing is not indicated), collodion, suspensions, emulsions (e.g., lotions), semisolids (e.g., foams, oint- Creams are semisolid dosage forms that contain one or ments, pastes, creams, and gels), solids (e.g., powders more drug substances dissolved or dispersed in a suitable and aerosols), and sprays. The physical characteristics base. This term traditionally has been applied to semi- of these dosage forms vary widely. solids that possess a relatively soft, spreadable consis- tency formulated as either water-in-oil or oil-in-water emulsions. However, more recently the term has been re- stricted to products consisting of oil-in-water emulsions a Correspondence should be addressed to: Margareth Marques, PhD, or aqueous microcrystalline dispersions of long-chain Senior Scientist, Documentary Standards Division, US Pharmacopeial fatty acids or alcohols that are water washable and more Convention, 12601 Twinbrook Parkway, Rockville, MD 20852-1790; cosmetically and aesthetically acceptable. tel. 301.816.8106; e-mail [email protected]. b Deceased. # 2009 The United States Pharmacopeial Convention, Inc. All Rights Reserved. STIMULI TO THE REVISION PROCESS Pharmacopeial Forum Stimuli articles do not necessarily reflect the policies Vol. 35(3) [May–June 2009] of the USPC or the USP Council of Experts 751 Emulsions 50% hydrocarbons, waxes, or polyols as the vehicle. Ointment bases recognized for use as vehicles fall into Emulsions are viscid, multiphase systems in which one four general classes: hydrocarbon bases, absorption or more liquids are dispersed throughout another immis- bases, water-removable bases, and water-soluble bases. cible liquid in the form of small droplets. When oil is the Each therapeutic ointment possesses as its base one of dispersed phase and an aqueous solution is the continu- these four general classes. ous phase, the system is designated as an oil-in-water emulsion. Conversely, when water or an aqueous solu- Hydrocarbon Bases—Hydrocarbon bases, known also tion is the dispersed phase and oil or oleaginous material as ‘‘oleaginous ointment bases,’’ are represented by is the continuous phase, the system is designated as a White Petrolatum and White Ointment (both USP). Only water-in-oil emulsion. Emulsions are stabilized by emulsi- small amounts of an aqueous component can be incor- fying agents that prevent coalescence, the merging of porated into these bases. Hydrocarbon bases serve to small droplets into larger droplets, and, ultimately, into keep medicaments in prolonged contact with the skin a single separated phase. Emulsifying agents (surfac- and act as occlusive dressings. These bases are used tants) act by concentrating at the interface between chiefly for their emollient effects and are difficult to wash the immiscible liquids, thereby providing a physical bar- off. They do not ‘‘dry out’’ or change noticeably on rier that reduces the tendency for coalescence. Surfac- aging. tants also reduce the interfacial tension between the phases, facilitating the formation of small droplets upon Absorption Bases—This class of bases may be divided mixing. The term emulsion is not used if a more specific into two groups: the first consists of bases that permit Stimuli to the Revision Process term is applicable, e.g., cream or ointment. the incorporation of aqueous solutions with the forma- tion of a water-in-oil emulsion (e.g., Hydrophilic Petrola- Foams tum and Lanolin, both USP), and the second group consists of water-in-oil emulsions that permit the incor- Foams are emulsified systems packaged in pressurized poration of additional quantities of aqueous solutions containers or special dispensing devices that contain dis- (Lanolin, USP). Absorption bases also are useful as persed gas bubbles, usually in a liquid continuous phase, emollients. that when dispensed has a fluffy, semisolid consistency. Water-removable Bases—Water-removable bases are Gels oil-in-water emulsions (e.g., Hydrophilic Ointment, USP), and are more correctly called ‘‘creams’’ (see Gels (sometimes called Jellies) are semisolid systems Creams, above). They also are described as ‘‘water-wash- consisting of either suspensions composed of small inor- able’’ because they may be readily washed from the skin ganic particles or large organic molecules interpene- or clothing with water, an attribute that makes them trated by a liquid. When the gel mass consists of a more acceptable for cosmetic purposes. Some medica- network of small discrete particles, the gel is classified ments may be more effective in these bases than in hy- as a two-phase system (e.g., Aluminum Hydroxide Gel, drocarbon bases. Other advantages of the water- USP). In a two-phase system if the particle size of the dis- removable bases are that they may be diluted with water persed phase is relatively large, the gel mass is sometimes and that they favor the absorption of serous discharges in referred to as a magma (e.g., Bentonite Magma, NF). dermatological conditions. Both gels and magmas may be thixotropic, forming semisolids after standing and becoming liquid when agi- Water-soluble Bases—This group of so-called ‘‘grease- tated. They should be shaken before use to ensure homo- less ointment bases’’ comprises water-soluble constitu- geneity and should be labeled to that effect (see Topical ents. Polyethylene Glycol Ointment, NF is the only Suspensions, below). Single-phase gels consist of organic pharmacopeial preparation in this group. Bases of this macromolecules uniformly distributed throughout a liq- type offer many of the advantages of the water-remova- uid with no apparent boundary between the dispersed ble bases and, in
Recommended publications
  • Using Rheology Measurement As a Potentially Predictive Tool for Solder Paste Transfer Efficiency and Print Volume Consistency
    USING RHEOLOGY MEASUREMENT AS A POTENTIALLY PREDICTIVE TOOL FOR SOLDER PASTE TRANSFER EFFICIENCY AND PRINT VOLUME CONSISTENCY Mitch Holtzer, Karen Tellefsen and Westin Bent Alpha Assembly Solutions South Plainfield, NJ, USA [email protected] ABSTRACT Commercially available solder pastes use an upper and Industry standards such as J-STD-005 and JIS Z 3284-1994 lower limit for viscosity. Generally, this viscosity is call for the use of viscosity measurement(s) as a quality measured at one shear rate, typically the shear associated assurance test method for solder paste. Almost all solder with a spiral viscometer rotating at 10 revolutions per paste produced and sold use a viscosity range at a single minute (RPM). If the powder contained in solder paste is shear rate as part of the pass fail criteria for shipment and dissolved by the acid activator in the solder paste flux, the customer acceptance respectively. viscosity of the solder paste will quickly increase. If the viscosity increases more than 20 to 30% above the upper As had been reported many times, an estimated 80% of the limit of the specification, poor printing results will be highly defects associated with the surface mount technology likely. The solder paste will not roll evenly over the stencil process involve defects created during the printing process. and apertures in the stencil will remain unfilled, causing Viscosity at a single shear rate could predict a fatal flaw in skips in the paste printing pattern. the printability of a solder paste sample. However, false positive single shear rate viscosity readings are not The purpose of the study was to determine if there is a unknown.
    [Show full text]
  • Transdermal Absorption Preparation
    Europäisches Patentamt *EP001522316A1* (19) European Patent Office Office européen des brevets (11) EP 1 522 316 A1 (12) EUROPEAN PATENT APPLICATION published in accordance with Art. 158(3) EPC (43) Date of publication: (51) Int Cl.7: A61K 47/34, A61K 47/10, 13.04.2005 Bulletin 2005/15 A61K 47/14, A61K 9/06, A61K 9/08, A61K 9/12, (21) Application number: 03764126.3 A61K 9/70 (22) Date of filing: 02.07.2003 (86) International application number: PCT/JP2003/008400 (87) International publication number: WO 2004/006960 (22.01.2004 Gazette 2004/04) (84) Designated Contracting States: • OMICHI, Katsuhiro AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Saitama-shi, Saitama 338-0832 (JP) HU IE IT LI LU MC NL PT RO SE SI SK TR • OKADA, Minoru Designated Extension States: Inzai-shi, Chiba 270-1323 (JP) AL LT LV MK • KURAZUMI, Toshiaki Narita-shi, Chiba 286-0011 (JP) (30) Priority: 16.07.2002 JP 2002206565 (74) Representative: Hartz, Nikolai F., Dr. (71) Applicant: SSP Co., Ltd. Wächtershäuser & Hartz Chuo-ku, Tokyo 103-8481 (JP) Patentanwälte Weinstrasse 8 (72) Inventors: 80333 München (DE) • NARUI, Takashi Sakura-shi, Chiba 285-0817 (JP) (54) TRANSDERMAL ABSORPTION PREPARATION (57) A transdermal absorption promotion composi- and transdermal absorption preparation not only exhibit tion comprising the following components (a), (b), and an excellent transdermal absorption promotion effect, (c) and a transdermal absorption preparation compris- but also exhibit superior skin-permeability, even if a drug ing the following components (a), (b), (c), and (d) are having a relatively high lipophilic property and poor disclosed.
    [Show full text]
  • Pricing Sheet
    Trusted Service. Proven Savings. Pharmacy: (325) 704-5222 Fax: (325) 777-4819 17 Windmill Circle Suite B Abilene, TX 79606 bigcountry.clarxpharmacy.com SureScript ID: 1171544616 Dermatology Compounds UPDATED 9/3/2020 Medication QTY Price Fluorouracil/ Calcipotriene Cream 4.5/ 0.005% 30 g $55 Fluorouracil Cream 4.5% or 1.5% 30 g $50 Wart Peel Cream (Salicylic Acid/ Fluorouracil 17/ 2%) 30 g $45 Ivermectin Lotion 1.5% 30 g $45 Double Rosacea Cream (Metronidazole/ Ivermectin 1/ 1%) 30 g $55 Triple Rosacea Cream (Azelaic Acid/ Metronidazole/ Ivermectin 15/ 1/ 1%) 30 g $45 Azelaic Acid Cream 17% 30 g $45 Calcipotriene/ Clobetasol Cream 0.005/ 0.045% 60 g $85 Clioquinol/ Hydrocortisone Cream 1/ 1% 30 g $55 Tretinoin Micro Cream 0.033/ 0.055/ 0.09% 45 g $55 Clindamycin/ Tretinoin Micro Cream 1/0.03% 30 g $75 Triamcinolone/ Hydroquinone/ Tretinoin Cream 0.025/ 4/ 0.05% 30 g $55 Hydrocortisone/ Hydroquinone/ Tretinoin Cream 2.5/ 8/ 0.05% 30 g $55 Hydroquinone/ Kojic Acid Cream 12/ 6% or 10/ 3% 30 g $65 Hydroquinone/ Tretinoin Cream 4/ 0.05% 30 g $65 Squaric Acid Solution 0.1 / 0.01 / 0.001% 15 ml $85 Urea Cream 35% 90 g $45 Dapsone 6% Cream 60 g $55 Costmetic Numbing Oint. (Lidocain 23%/Tetracain 7%) 60g $35 General topical compound pricing for other compounds QTY Price Variations to the compounds above will fall into the pricing below. One Active Ingredient 30g $79 Two Active Ingredients 30g $89 Three Active Ingredients 30g $99 *This applies to most compounds (90%) not all, if exceptionally expensive we will call the office to discuss* All cash, no rebates or insurance to mess with! Medicare patients get medications at these great prices too! Free Delivery in 3-5 business days for compounds Page 1 Trusted Service.
    [Show full text]
  • Orally Inhaled & Nasal Drug Products
    ORALLY INHALED & NASAL DRUG PRODUCTS: INNOVATIONS FROM MAJOR DELIVERY SYSTEM DEVELOPERS www.ondrugdelivery.com 00349_GF_OnDrugDelivery349_GF_OnDrugDelivery PulmonaryPulmonary NasalNasal NovemberNovember 2010.indd2010.indd 1 330/11/100/11/10 111:32:331:32:33 “Orally Inhaled & Nasal Drug Products: Innovations from Major Delivery CONTENTS System Developers” This edition is one in the ONdrugDelivery series of pub- Innovation in Drug Delivery by Inhalation lications from Frederick Furness Publishing. Each issue focuses on a specific topic within the field of drug deliv- Andrea Leone-Bay, Vice-President, Pharmaceutical ery, and is supported by industry leaders in that field. Development, Dr Robert Baughman, Vice-President, Clinical Pharmacology & Bioanalytics, Mr Chad EDITORIAL CALENDAR 2011: Smutney, Senior Director, Device Technology, February: Prefilled Syringes Mr Joseph Kocinsky, Senior Vice-President, March: Oral Drug Delivery & Advanced Excipients Pharmaceutical Technology Development April: Pulmonary & Nasal Drug Delivery (OINDP) MannKind Corporation 4-7 May: Injectable Drug Delivery (Devices Focus) June: Injectable Drug Delivery (Formulations Focus) Current Innovations in Dry Powder Inhalers September: Prefilled Syringes Richard Sitz, Technical Manager, DPI Technology October: Oral Drug Delivery Platform Leader November: Pulmonary & Nasal Drug Delivery (OINDP) 3M Drug Delivery Systems 10-12 December: Delivering Biologics (Proteins, Peptides & Nucleotides) Pulmonary Delivery & Dry-Powder Inhalers: SUBSCRIPTIONS: Advances in Hard-Capsule
    [Show full text]
  • An Introduction to Fast Dissolving Oral Thin Film Drug Delivery Systems: a Review
    Muthadi Radhika Reddy /J. Pharm. Sci. & Res. Vol. 12(7), 2020, 925-940 An Introduction to Fast Dissolving Oral Thin Film Drug Delivery Systems: A Review Muthadi Radhika Reddy1* 1School of pharmacy, Gurunanak Institute of Technical Campus, Hyderabad, Telangana, India and Department of Pharmacy, Gandhi Institute of Technology and Management University, Vizag, Andhra Pradesh, India INTRODUCTION 2. Useful in situations where rapid onset of action Fast dissolving drug delivery systems were first developed required such as in motion sickness, allergic attack, in the late 1970s as an alternative to conventional dosage coughing or asthma forms. These systems consist of solid dosage forms that 3. Has wide range of applications in pharmaceuticals, Rx disintegrate and dissolve quickly in the oral cavity without Prescriptions and OTC medications for treating pain, the need of water [1]. Fast dissolving drug delivery cough/cold, gastro-esophageal reflux disease,erectile systems include orally disintegrating tablets (ODTs) and dysfunction, sleep disorders, dietary supplements, etc oral thin films (OTFs). The Centre for Drug Evaluation [4] and Research (CDER) defines ODTs as,“a solid dosage 4. No water is required for the administration and hence form containing medicinal substances which disintegrates suitable during travelling rapidly, usually within a matter of seconds, when placed 5. Some drugs are absorbed from the mouth, pharynx upon the tongue” [2]. USFDA defines OTFs as, “a thin, and esophagus as the saliva passes down into the flexible, non-friable polymeric film strip containing one or stomach, enhancing bioavailability of drugs more dispersed active pharmaceutical ingredients which is 6. May offer improved bioavailability for poorly water intended to be placed on the tongue for rapid soluble drugs by offering large surface area as it disintegration or dissolution in the saliva prior to disintegrates and dissolves rapidly swallowing for delivery into the gastrointestinal tract” [3].
    [Show full text]
  • Dispensing Solder Paste with a Noflex™ Linear Drive System
    AIRFREE™ WHITE PAPER LDS9000 VS. AUGER VALVE DISPENSERS Dispensing Solder Paste with a NoFlex™ Linear Drive System By: Scott Beebe, President of Fishman Corporation While the limitations of pneumatics in dispensing solder paste are well understood, higher board densities and smaller dot sizes are also challenging the performance abilities of more advanced types of dispensers, such as auger valves. AirFreeTM Linear Drive technology offers promising benefits, including significant savings in material cost and high repeatability without concern for viscosity and the volume of paste remaining in the syringe. The process of dispensing solder paste began with pneumatics. Whether a hand-held gun, or an automated workstation, whether a diaphragm, spool, needle, or piston, such dispensers depend on a column of air under pressure to force material through a dispensing tip and onto a substrate. Heat, moisture, fluctuations in air pressure, contamination, changes in viscosity... all undermine the ability of air-driven dispensers to deliver prescribed amounts of solder paste consistently, especially in the small amounts required by high density electronic circuitry (typically, less than a milligram). While pneumatic dispensers were at one time the only method available for hand-held and automatic dispensing of solder paste, the demand for precise volume control and repeatability led to the development of alternative solutions in dispensing, the most notable being the auger valve. Unfortunately, auger valves have limitations. Linear Drive technology, however, isunique, in that the amount of solder paste delivered—dot after dot after dot—is consistent, by design, and is unaffected by either changes in viscosity (Figure 1) or the amount of paste left in the syringe.* Moreover, cost savings can be substantial due to the ability to pre-package syringes with larger amounts of paste than is possible with other types of dispensers.
    [Show full text]
  • Cream LOTRISONE® Lotion (Clotrimazole and Betamethasone Dipropionate)
    LOTRISONE® Cream LOTRISONE® Lotion (clotrimazole and betamethasone dipropionate) FOR TOPICAL USE ONLY. NOT FOR OPHTHALMIC, ORAL, OR INTRAVAGINAL USE. NOT RECOMMENDED FOR PATIENTS UNDER THE AGE OF 17 YEARS AND NOT RECOMMENDED FOR DIAPER DERMATITIS. DESCRIPTION LOTRISONE® Cream and Lotion contain combinations of clotrimazole, a synthetic antifungal agent, and betamethasone dipropionate, a synthetic corticosteroid, for dermatologic use. Chemically, clotrimazole is 1–(o-chloro-α,α-diphenylbenzyl) imidazole, with the empirical formula C22H17CIN2, a molecular weight of 344.84, and the following structural formula: Clotrimazole is an odorless, white crystalline powder, insoluble in water and soluble in ethanol. Betamethasone dipropionate has the chemical name 9-fluoro-11β,17,21- trihydroxy-16β-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate, with the empirical formula C28H37FO7, a molecular weight of 504.59, and the following structural formula: 1 LRN# 000370-LOS-MTL-USPI-1 Betamethasone dipropionate is a white to creamy white, odorless crystalline powder, insoluble in water. Each gram of LOTRISONE Cream contains 10 mg clotrimazole and 0.643 mg betamethasone dipropionate (equivalent to 0.5 mg betamethasone), in a hydrophilic cream consisting of purified water, mineral oil, white petrolatum, cetyl alcohol plus stearyl alcohol, ceteareth-30, propylene glycol, sodium phosphate monobasic monohydrate, and phosphoric acid; benzyl alcohol as preservative. LOTRISONE Cream may contain sodium hydroxide. LOTRISONE Cream is smooth, uniform, and white to off-white in color. Each gram of LOTRISONE Lotion contains 10 mg clotrimazole and 0.643 mg betamethasone dipropionate (equivalent to 0.5 mg betamethasone), in a hydrophilic base of purified water, mineral oil, white petrolatum, cetyl alcohol plus stearyl alcohol, ceteareth-30, propylene glycol, sodium phosphate monobasic monohydrate, and phosphoric acid; benzyl alcohol as a preservative.
    [Show full text]
  • Drug Delivery Technology Y
    * DDT Nov-Dec 2007 Working 11/9/07 2:29 PM Page 1 November/December 2007 Vol 7 No 10 IN THIS ISSUE Company Profiles 12 Drug Delivery Technologies 58 Excipients, Polymers, Liposomes & Lipids 78 Contract Pharmaceutical & Biological Development Services 83 Machinery & Laboratory Equipment and Software 96 Technology Showcase 102 The science & business of specialty pharma, biotechnology, and drug delivery www.drugdeliverytech.com * DDT Nov-Dec 2007 Working 11/9/07 2:39 PM Page 2 * DDT Nov-Dec 2007 Working 11/9/07 2:40 PM Page 3 * DDT Nov-Dec 2007 Working 11/9/07 2:40 PM Page 4 November/December 2007 Vol 7 No 10 PUBLISHER/PRESIDENT Ralph Vitaro EXECUTIVE EDITORIAL DIRECTOR Dan Marino, MSc [email protected] CREATIVE DIRECTOR Shalamar Q. Eagel CONTROLLER Debbie Carrillo CONTRIBUTING EDITORS Cindy H. Dubin Debra Bingham Jason McKinnie TECHNICAL OPERATIONS Mark Newland EDITORIAL SUPPORT Nicholas D. Vitaro ADMINISTRATIVE SUPPORT Kathleen Kenny Corporate/Editorial Office 219 Changebridge Road, Montville, NJ 07045 Tel: (973)299-1200 Fax: (973) 299-7937 www.drugdeliverytech.com Advertising Sales Offices East & Midwest Victoria Geis - Account Executive Coming in 2008 Cheryl S. Stratos - Account Executive 103 Oronoco Street, Suite 200 Alexandria, VA 22314 Tel: (703) 212-7735 Drug Delivery Weekly & Fax: (703) 548-3733 E-mail: [email protected] Specialty Pharma News E-mail: [email protected] West Coast Warren De Graff Western Regional Manager 818 5th Avenue, Suite 301 San Rafael, CA 94901 Tel: (415) 721-0644 Fax: (415) 721-0665 E-mail: [email protected] 0 The weekly electronic newsletter from the publishers of Drug 1 International o N Delivery Technology and Specialty Pharma will provide over 12,000 Ralph Vitaro 7 219 Changebridge Road l o subscribers with the latest news of business deals, alliances, and V Montville, NJ 07045 Tel: (973) 299-1200 7 technology breakthroughs from the pharmaceutical, specialty 0 Fax: (973) 299-7937 0 2 pharmaceutical, drug delivery, and biotechnology industries.
    [Show full text]
  • Making Dry Eyes Ancient History: Egypt, Mesopotamia, India, China, Greece and Rome
    Making Dry Eyes Ancient History: Egypt, Mesopotamia, India, China, Greece and Rome Cheryl Lynn Bergin, OD Author’s Bio Dr. Bergin teaches Anatomy and Physiology at St. Louis Community College. She writes about systemic nutrition, ocular nutrition and the ocular effects of eating disorders. She is a member of the Optometric (Ocular) Nutrition and Optometric Historical Societies. Photo by Stan Trampe ________________________________________________________________________________ Dry eyes are not a new condition, but one might think that the case. A literature search for “dry eye” rarely reveals anything before 1970. One must be an ocular archeologist to discover how the ancients treated “irritated” eyes, dried by the harsh conditions of the desert sun and sand. EGYPT: In 1872, Georg Ebers, a German Egyptologist and novelist, discovered a collection of Egyptian medicinal recipes later called the Ebers Papyrus. The papyrus also contains ancient ophthalmic treatments. Ebers selected the important chapters on ocular diseases, translated them and added explanatory remarks. Written between 1553 and 1550 BC (1,000 years before Hippocrates), this is the oldest book on medicine (perhaps the medical textbook of ancient Egypt). It is similar to the Greek manuscripts about folk medicine that can be found among the collection of Galen and Oribasius, as well as among the manuscripts of Dioscorides. According to Ebers Papyrus, “The water within,” i.e., tear fluid and mucous secretion, is treated with incense, myrrh, and lead salt.”6,9 EGYPTIAN EYE MAKE-UP: Liz Taylor as Cleopatra16 The ancient Egyptian’s eye make-up was not just stunning, it was functional. It helped alleviate irritation from the sun’s glare off the desert sand and even prevented eye infections.
    [Show full text]
  • Mometasone Powder Rationale for Inclusion In
    MOMETASONE POWDER RATIONALE FOR INCLUSION IN PA PROGRAM Background Mometasone is a corticosteroid demonstrating potent anti-inflammatory activity able to decrease inflammation through a mechanism of action that is not known. However, corticosteroids are thought to act by the induction of phospholipase A2, which leads to the inhibition of a common precursor for potent inflammatory mediators. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption (1). Mometasone is commercially available in the following dosage forms: topical cream, topical lotion, topical ointment, nasal spray and as a powder for inhalation. Regulatory Status FDA approved topical indication: Mometasone is a corticosteroid indicated for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 2 years of age and older (1). The safety and efficacy of mometasone have not been established in pediatric patients below 2 years of age (1). Summary Topical steroids have anti-inflammatory, antipruritic, and vasoconstrictive properties. Mometasone is FDA-approved for inflammatory and pruritic manifestations of corticosteroid- responsive dermatoses in patients 2 years of age and older. The safety and efficacy of mometasone have not been established in pediatric patients below 2 years of age (1). Mometasone is commercially available in the following dosage forms: topical cream, topical lotion, topical ointment, nasal spray and as powder for inhalation. Mometasone powder may be considered medically necessary in a topical formulation for patients 2 years of age or older for the treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Mometasone powder may be considered investigational in a topical formulation for patients Mometasone Powder FEP Clinical Rationale MOMETASONE POWDER under the age of 2 years, or in patients without a diagnosis of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
    [Show full text]
  • Salicylic Acid
    Treatment Guide to Common Skin Conditions Prepared by Loren Regier, BSP, BA, Sharon Downey -www.RxFiles.ca Revised: Jan 2004 Dermatitis, Atopic Dry Skin Psoriasis Step 1 - General Treatment Measures Step 1 - General Treatment Measures Step 1 • Avoid contact with irritants or trigger factors • Use cool air humidifiers • Non-pharmacologic measures (general health issues) • Avoid wool or nylon clothing. • Lower house temperature (minimize perspiration) • Moisturizers (will not clear skin, but will ↓ itching) • Wash clothing in soap vs detergent; double rinse/vinegar • Limit use of soap to axillae, feet, and groin • Avoid frequent or prolonged bathing; twice weekly • Topical Steroids Step 2 recommended but daily bathing permitted with • Coal Tar • Colloidal oatmeal bath products adequate skin hydration therapy (apply moisturizer • Anthralin • Lanolin-free water miscible bath oil immediately afterwards) • Vitamin D3 • Intensive skin hydration therapy • Limit use of soap to axillae, feet, and groin • Topical Retinoid Therapy • “Soapless” cleansers for sensitive skin • Apply lubricating emollients such as petrolatum to • Sunshine Step 3 damp skin (e.g. after bathing) • Oral antihistamines (1st generation)for sedation & relief of • Salicylic acid itching give at bedtime +/- a daytime regimen as required Step 2 • Bath additives (tar solns, oils, oatmeal, Epsom salts) • Topical hydrocortisone (0.5%) for inflammation • Colloidal oatmeal bath products Step 2 apply od-tid; ointments more effective than creams • Water miscible bath oil • Phototherapy (UVB) may use cream during day & ointment at night • Humectants: urea, lactic acid, phospholipid • Photochemotherapy (Psoralen + UVA) Step 4 Step 3 • Combination Therapies (from Step 1 & 2 treatments) • Prescription topical corticosteroids: use lowest potency • Oral antihistamines for sedation & relief of itching steroid that is effective and wean to twice weekly.
    [Show full text]
  • TOXICOLOGY and EXPOSURE GUIDELINES ______(For Assistance, Please Contact EHS at (402) 472-4925, Or Visit Our Web Site At
    (Revised 1/03) TOXICOLOGY AND EXPOSURE GUIDELINES ______________________________________________________________________ (For assistance, please contact EHS at (402) 472-4925, or visit our web site at http://ehs.unl.edu/) "All substances are poisons; there is none which is not a poison. The right dose differentiates a poison and a remedy." This early observation concerning the toxicity of chemicals was made by Paracelsus (1493- 1541). The classic connotation of toxicology was "the science of poisons." Since that time, the science has expanded to encompass several disciplines. Toxicology is the study of the interaction between chemical agents and biological systems. While the subject of toxicology is quite complex, it is necessary to understand the basic concepts in order to make logical decisions concerning the protection of personnel from toxic injuries. Toxicity can be defined as the relative ability of a substance to cause adverse effects in living organisms. This "relative ability is dependent upon several conditions. As Paracelsus suggests, the quantity or the dose of the substance determines whether the effects of the chemical are toxic, nontoxic or beneficial. In addition to dose, other factors may also influence the toxicity of the compound such as the route of entry, duration and frequency of exposure, variations between different species (interspecies) and variations among members of the same species (intraspecies). To apply these principles to hazardous materials response, the routes by which chemicals enter the human body will be considered first. Knowledge of these routes will support the selection of personal protective equipment and the development of safety plans. The second section deals with dose-response relationships.
    [Show full text]